Sort
82,697 grants matching “vaccine development”
Southeast Regional Centers of Excellence for Biodefense & Emerging Infectious Di
$3,986,633Philip Frederick Sparling · Univ Of North Carolina Chapel Hill · U54 · FY2009 · AI
Defense against Biowarfare and Emerging Infection Agents
$3,986,438University Of Maryland Baltimore · U54 · FY2003 · AI
Tuberculosis Imaging Program
$3,984,712Steven Holland · National Institute Of Allergy And Infectious Diseases · ZIC · FY2018 · AI
Biodefense and Emerging Infectious Disease Monoclonal Antibody Studies
$3,982,599Julie E. Ledgerwood · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies
$3,981,157John P Moore · Weill Medical Coll Of Cornell Univ · P01 · FY2016 · AI
PAR04-122, Extramural Research Facilities Construction:*
$3,978,104Mark Joseph Rudin · Boise State University · C06 · FY2010 · RR
The humoral response to Zika virus infection and vaccination
$3,976,172Theodore Pierson · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine
$3,974,723Thomas Hassell · International Aids Vaccine Initiative · N01 · FY2022 · AI
North Carolina Seronet Center for Excellence
$3,974,612Ralph S Baric · Univ Of North Carolina Chapel Hill · U54 · FY2020 · CA
Adjuvant development in the context of seasonal and pandemic influenza
$3,971,336Jay Evans · University Of Montana · N01 · FY2020 · AI
Northeast Biodefense Center
$3,970,912Wadsworth Center · U54 · FY2003 · AI
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses
$3,968,419Fred R Hirsch · Icahn School Of Medicine At Mount Sinai · U54 · FY2020 · CA
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
$3,963,391Ignacio E. Sanz · Emory University · U54 · FY2020 · CA
Project 4: Vaccine Design [insect alphavirus chimera] VEEV/CHIKV (alphaviruses)
$3,960,456Scott C Weaver · Washington University · U19 · FY2024 · AI
TB-RICC 3.0
$3,960,184Jerrold J. Ellner · Rutgers Biomedical And Health Sciences · U01 · FY2024 · AI
Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site
$3,959,354Karen L. Kotloff · University Of Maryland Baltimore · UM1 · FY2022 · AI
Harnessing CD4+ T cell responses for long-term protective immunity against HIV
$3,958,312Rafi Ahmed · Scripps Research Institute, The · UM1 · FY2013 · AI
NIAID PRECLINICAL DEVELOPMENT SUPPORT - PRODUCTION OF HIV-1 gp120 PROTEIN
$3,954,971Nancy Lin · Advanced Bioscience Laboratories, Inc. · N01 · FY2014 · AI
FEND for TB
$3,954,651Jerrold J. Ellner · Rbhs-New Jersey Medical School · U01 · FY2021 · AI
UCLA AIDS Prevention and Treatment Clinical Trials Unit
$3,954,316Judith S. Currier · University Of California Los Angeles · UM1 · FY2024 · AI
Project 2: mRNA vaccine development against Bunyaviruses, Paramyxoviruses and Picornaviruses
$3,953,703Norbert Pardi · University Of California-Irvine · U19 · FY2024 · AI
Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP-COVID)
$3,952,831Eugene M. Oltz · Ohio State University · U54 · FY2020 · CA
HIV Preventive Vaccine Studies
$3,952,801Barney Graham · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
MALARIA VACCINE EVALUATION
$3,951,837Christopher Case · Leidos Biomedical Research, Inc. · N01 · FY2015 · CA
Center for AIDS Research at Emory University
$3,951,309Carlos Del Rio · Emory University · P30 · FY2020 · AI